New drug tested for Tough-to-Treat blood cancer
NCT ID NCT03698552
Summary
This study tested a new drug called ADCT-602 for adults with a fast-growing blood cancer (B-cell acute lymphoblastic leukemia) that has come back or stopped responding to standard treatments. The main goals were to find a safe and effective dose and to see if the drug could help control the cancer. The trial was terminated early and enrolled 37 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer
Monrovia, California, 91016, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.